We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests
Read MoreHide Full Article
Key Takeaways
Hologic gained FDA clearance and CE marking for its Panther Fusion GI bacterial assays.
HOLX shares climbed 1.3% to $67.91 after the approval of the new diagnostic tests.
Hologic's assays detect major GI pathogens, offering faster, more tailored patient testing.
Hologic, Inc. (HOLX - Free Report) recently received FDA 510(k) clearance for its Panther Fusion Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. Additionally, the assays obtained CE marking in the European Union in accordance with the In Vitro Diagnostic Regulation.
These highly sensitive molecular tests are designed to rapidly detect the most common bacterial pathogens responsible for infectious gastroenteritis.
Likely Trend of HOLX Stock Following the News
Following the announcement, shares of the company surged 1.3% to $67.91 yesterday.
The company’s Molecular Diagnostics assays, which run on Panther and Panther Fusion systems, remain the principal revenue-generating component in the Diagnostics division. A key catalyst for Diagnostics’ sustained growth is the expanding global installed base of Panther instruments. Accordingly, we expect the latest development to bolster investor confidence and maintain an upward momentum in HOLX's share price in the upcoming days.
Hologic currently has a market capitalization of $15.10 billion. The company’s earnings yield of 6.7% compares favorably to the industry’s -4.3%. It delivered an average earnings surprise of 0.96% for the trailing four quarters.
More on Hologic’s New Assays
Traditionally, identifying pathogens causing severe diarrheal illness has required the combination of culture, biochemical and microscopy-based tests, which can be labor-intensive, time-consuming and less sensitive than molecular methods. Hologic’s new GI pathogen detection tests leverage rapid molecular technology and cover common bacterial causes of infectious gastroenteritis, including Salmonella, Campylobacter, Shigella, E. coli (including O157), Vibrio, Yersinia and Plesiomonas, and can be run together or in any combination.
In this customizable mini-panel format, the new assays allow testing to be specific and tailored to patients’ needs. This approach also helps reduce testing, streamline lab processes and accelerate time to diagnosis and clinical management. In the long term, it supports antimicrobial stewardship by enabling the judicious use of antibiotics.
Testing of the Panther Fusion GI Bacterial and Expanded Bacterial Assays is performed using Hologic’s trusted Panther Fusion System, an addition to the Panther System.
Image Source: Zacks Investment Research
About HOLX’s Panther and Panther Fusion Systems
The Panther System is a best-in-class, fully automated sample-to-result molecular diagnostics platform suitable for use in low, medium, or high-throughput laboratories. With a small footprint, adaptable workflow options, and a consolidated testing menu, it provides testing for women’s health, sexually transmitted infections, respiratory infections, viral load, transplant viruses, and now infectious gastroenteritis. The Panther Fusion module provides an expanded and growing in vitro diagnostics menu, as well as Open Access functionality, to run laboratory-developed tests.
Industry Prospects Favor HOLX
Infectious gastroenteritis, caused by bacteria, viruses, or parasites, can range from mild to severe. Per researchers, in the United States alone, it is estimated that nearly 200 million cases occur annually, including up to 3 million that require ambulatory visits. Per analysts, foodborne outbreaks across Europe have resulted in the highest numbers of related hospitalizations and deaths recorded in a decade, with Salmonella accounting for the largest proportion of cases.
Per a report by Persistence Market Research, the global gastrointestinal infection testing market is predicted to reach a size of $467.2 million by 2025. It is anticipated to witness a CAGR of 5.2% during the period to attain a value of $617.7 million by 2032.
Another Development by HOLX
Hologic unveiled favorable data from two groundbreaking studies evaluating its AI-powered mammography technology, the Genius AI Detection solution, at the European Society of Breast Imaging Annual Scientific Meeting in Aberdeen, Scotland. Research suggests that artificial intelligence may aid in identifying more aggressive forms of breast cancer and demonstrate performance comparable to that of expert radiologists in screening.
HOLX Stock Price Performance
In the past year, Hologic’s shares have risen 18.9% compared with the industry’s 2.3% growth.
Masimo’s shares have jumped 18.9% in the past year. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%.
Shares of Phibro have surged 76.5% in the past year compared with the industry’s 3.4% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%.
Shares of Boston Scientific have rallied 16.7% in the past year compared with the industry’s 5.2% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests
Key Takeaways
Hologic, Inc. (HOLX - Free Report) recently received FDA 510(k) clearance for its Panther Fusion Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. Additionally, the assays obtained CE marking in the European Union in accordance with the In Vitro Diagnostic Regulation.
These highly sensitive molecular tests are designed to rapidly detect the most common bacterial pathogens responsible for infectious gastroenteritis.
Likely Trend of HOLX Stock Following the News
Following the announcement, shares of the company surged 1.3% to $67.91 yesterday.
The company’s Molecular Diagnostics assays, which run on Panther and Panther Fusion systems, remain the principal revenue-generating component in the Diagnostics division. A key catalyst for Diagnostics’ sustained growth is the expanding global installed base of Panther instruments. Accordingly, we expect the latest development to bolster investor confidence and maintain an upward momentum in HOLX's share price in the upcoming days.
Hologic currently has a market capitalization of $15.10 billion. The company’s earnings yield of 6.7% compares favorably to the industry’s -4.3%. It delivered an average earnings surprise of 0.96% for the trailing four quarters.
More on Hologic’s New Assays
Traditionally, identifying pathogens causing severe diarrheal illness has required the combination of culture, biochemical and microscopy-based tests, which can be labor-intensive, time-consuming and less sensitive than molecular methods. Hologic’s new GI pathogen detection tests leverage rapid molecular technology and cover common bacterial causes of infectious gastroenteritis, including Salmonella, Campylobacter, Shigella, E. coli (including O157), Vibrio, Yersinia and Plesiomonas, and can be run together or in any combination.
In this customizable mini-panel format, the new assays allow testing to be specific and tailored to patients’ needs. This approach also helps reduce testing, streamline lab processes and accelerate time to diagnosis and clinical management. In the long term, it supports antimicrobial stewardship by enabling the judicious use of antibiotics.
Testing of the Panther Fusion GI Bacterial and Expanded Bacterial Assays is performed using Hologic’s trusted Panther Fusion System, an addition to the Panther System.
Image Source: Zacks Investment Research
About HOLX’s Panther and Panther Fusion Systems
The Panther System is a best-in-class, fully automated sample-to-result molecular diagnostics platform suitable for use in low, medium, or high-throughput laboratories. With a small footprint, adaptable workflow options, and a consolidated testing menu, it provides testing for women’s health, sexually transmitted infections, respiratory infections, viral load, transplant viruses, and now infectious gastroenteritis. The Panther Fusion module provides an expanded and growing in vitro diagnostics menu, as well as Open Access functionality, to run laboratory-developed tests.
Industry Prospects Favor HOLX
Infectious gastroenteritis, caused by bacteria, viruses, or parasites, can range from mild to severe. Per researchers, in the United States alone, it is estimated that nearly 200 million cases occur annually, including up to 3 million that require ambulatory visits. Per analysts, foodborne outbreaks across Europe have resulted in the highest numbers of related hospitalizations and deaths recorded in a decade, with Salmonella accounting for the largest proportion of cases.
Per a report by Persistence Market Research, the global gastrointestinal infection testing market is predicted to reach a size of $467.2 million by 2025. It is anticipated to witness a CAGR of 5.2% during the period to attain a value of $617.7 million by 2032.
Another Development by HOLX
Hologic unveiled favorable data from two groundbreaking studies evaluating its AI-powered mammography technology, the Genius AI Detection solution, at the European Society of Breast Imaging Annual Scientific Meeting in Aberdeen, Scotland. Research suggests that artificial intelligence may aid in identifying more aggressive forms of breast cancer and demonstrate performance comparable to that of expert radiologists in screening.
HOLX Stock Price Performance
In the past year, Hologic’s shares have risen 18.9% compared with the industry’s 2.3% growth.
HOLX’s Zacks Rank & Key Picks
Hologic currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Phibro Animal Health (PAHC - Free Report) and Boston Scientific (BSX - Free Report) . While Masimo and Phibro sport a Zacks Rank #1 (Strong Buy) each, Boston Scientific carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s shares have jumped 18.9% in the past year. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%.
Shares of Phibro have surged 76.5% in the past year compared with the industry’s 3.4% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%.
Shares of Boston Scientific have rallied 16.7% in the past year compared with the industry’s 5.2% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.